

# EU warns antibody drugs poor against new COVID strains

December 9 2022

---



Credit: Pixabay/CC0 Public Domain

The EU's drug watchdog warned on Friday that antibody treatments for COVID are ineffective against the newest and increasingly dominant strains of the disease.

Numerous monoclonal antibodies, which are given by injection or infusion in hospital, have helped blunt the worst of the disease for at-risk or hospitalized [patients](#).

They work by targeting the spike protein of the virus.

But the European Medicines Agency (EMA) "cautioned (they) are unlikely to be effective against emerging strains".

Lab tests showed they "are poorly effective at neutralizing Omicron strains BA.4.6, BA.2.75.2 and XBB," the Amsterdam-based regulator said in a statement.

They also "do not significantly neutralize BQ.1 and BQ.1.1, which are expected to become the dominant [strains](#) in the EU in the coming weeks".

The main antibody treatments include AstraZeneca's Evusheld, Roche's Ronapreve, and GSK and Vir's Xevudy.

Antiviral treatments such as Pfizer's Paxlovid are expected to remain effective and so EU states should stock up on them for [high-risk patients](#), the EMA said.

Monoclonal antibodies had been shown to reduce the risk of hospitalization and [death](#) by up to 80 percent, but they have lost their edge as the virus has mutated.

The World Health Organization in September recommended against using Xevudy and Ronapreve because they had stopped being effective against new variants.

COVID has kept evolving since it emerged in China at the end of 2019

to cause a global pandemic that is now waning.

While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sub-lineages have dominated throughout 2022 and look set to continue into 2023.

© 2022 AFP

Citation: EU warns antibody drugs poor against new COVID strains (2022, December 9)  
retrieved 26 April 2024 from

<https://medicalxpress.com/news/2022-12-eu-antibody-drugs-poor-covid.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.